ライフサイエンスコーパス: neutrophil count

1 /m2 weekly, with dose adjusted each week for neutrophil count).

2 d-type (WT), primarily driven by an elevated neutrophil count.

3 n alanine transaminase level or decreases in neutrophil count.

4 vels than wild-type mice, presented elevated neutrophil count.

5 s in CD4 cell count, but not by increases in neutrophil count.

6 these 52 molecules correlated with BAL fluid neutrophil counts.

7 in cholesterol levels and with reductions in neutrophil counts.

8 protein cholesterol levels and reductions in neutrophil counts.

9 in eosinophil counts and 64% of variation in neutrophil counts.

10 or treatment normalized CXCR4 expression and neutrophil counts.

11 of cotransplanted Tregs exhibited diminished neutrophil counts.

12 t produce mature T cells but maintain normal neutrophil counts.

13 s might contribute to regulating circulating neutrophil counts.

14 had the greatest effects on regulating blood neutrophil counts.

15 h IL-23, but not IL-12, restored circulating neutrophil counts.

16 velopment, but is not necessary for elevated neutrophil counts.

17 vivo and should therefore improve peripheral neutrophil counts.

18 d by beta 2 integrin expression and systemic neutrophil counts.

19 also decreased platelet counts and increased neutrophil counts.

20 neutropenia inter-spaced with (near) normal neutrophil counts.

21 ts (0.16 x 10(9) cells/L; P = 0.014), higher neutrophil counts (0.11 x 10(9) cells/L; P = 0.026), and

22 nce, 0.89 x 10(9) cells/L; P < 0.001), lower neutrophil counts (0.83 x 10(9) cells/L; P < 0.001), and

23 bin concentration 9 g/dL or higher, absolute neutrophil count 1 x 10(3) cells per mm(3) or higher, an

24 ase 9.6 g/L, 95% CI 7.6-11.6 g/L; p<0.0001), neutrophil counts (1.1x10(9)/L, 0.7-1.5x10(9)/L; p<0.000

25 anaemia (14 [9%] vs 26 [17%]), and decreased neutrophil count (11 [7%] vs 17 [11%]).

26 ression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet count 70,000

27 common grade 3 or 4 adverse events were low neutrophil count (15 [11%] preoperatively in the chemoth

28 1 [16%] in the CRT only group), low absolute neutrophil count (15 [12%] vs 24 [19%]), fatigue (26 [20

29 in the safety population (n=57) were reduced neutrophil count (15 [26%]), hypophosphatemia (11 [19%])

30 mmon grade 3-4 adverse events were decreased neutrophil count (210 [37%] in the cetuximab group vs 15

31 lic blood pressure and a 32% decrease in the neutrophil count 24 h after treatment with formulation A

32 spnoea (35 [12%] of 289 patients), decreased neutrophil count (26 [9%]), and fatigue (23 [8%]).

33 t common serious adverse event was decreased neutrophil count: 26 episodes in 14 participants.

34 1 [11%]), dyspnoea (29 [10%]), and decreased neutrophil count (28 [10%]), and with pemetrexed alone w

35 , leucopenia (22 [7%] vs 17 [6%]), decreased neutrophil count (31 [10%] vs 41 [13%]), and decreased w

36 ients), leucopenia (42 [16%]), and decreased neutrophil count (40 [15%]); in the placebo plus paclita

37 te blood cell count (11600/microL), absolute neutrophil count (4100/microL), and platelet count (362

38 vacizumab group), and infections with normal neutrophil count (42 events vs 53).

39 ide levels (38 vs 27 ppb, P = .02) and blood neutrophil counts (5.3 vs 4.0 10(9)/L, P </= .001) and s

40 All patients engrafted to an absolute neutrophil count 500/microL at a median of 13 days (rang

41 Adjusted HRs comparing neutrophil counts 6 to 7 versus 2 to 3 x 10(9)/l (both w

42 x 1000 cells/muL [IQR, 7.5, 12.9]; P = .01), neutrophil count (6.7 x 1000 cells/muL [IQR, 2.8, 9.7] v

43 t was correlated to the CD66b microparticles/neutrophil count, a surrogate of neutrophil activation a

44 ether age, FEV1 percent predicted, and blood neutrophil counts accurately predict sputum neutrophil p

45 ed granulocyte-colony stimulating factor and neutrophil counts/activity postsuboptimal immunization.

46 GP generation correlates closely with airway neutrophil counts after administration of proteases in v

47 Neutrophil counts after trial entry rose significantly m

48 For two traits, lipoprotein(a) levels and neutrophil count, aggregate tests of low-frequency and r

49 Mean baseline neutrophil counts also varied significantly by genotype:

50 Obesity and high neutrophil counts also worsened the PM effects with or w

51 responses, we found significantly different neutrophil counts among treatments; however, phagocytic

52 bones, a markedly enlarged spleen, elevated neutrophil counts, an enlarged heart, and behavioral hyp

53 caused a dose-dependent decrease in absolute neutrophil count (ANC) and reduced inflammatory biomarke

54 The median absolute neutrophil count (ANC) at diagnosis was 0.4 x 10(9)/L, a

55 ine neutropenia, 82% of those whose absolute neutrophil count (ANC) decreased by > or = 75% achieved

56 n therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL and platel

57 The mean time to absolute neutrophil count (ANC) more than 500/mm(3) was 9 +/- 0.6

58 ivariate and multivariate models of absolute neutrophil count (ANC) nadir and pharmacokinetic paramet

59 teria: positive CSF Gram stain, CSF absolute neutrophil count (ANC) of at least 1000 cells/microL, CS

60 , but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 x 10(9)/L [

61 Median time to recovery of absolute neutrophil count (ANC) was 12 days.

62 commercial G-CSF on the increase of absolute neutrophil counts (ANC).

63 The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms

64 blood with normalization of counts (absolute neutrophil count [ANC]> 1.5 x 10(9)/L, hemoglobin [Hgb]

65 mation (alkaline phosphatase [ALP], absolute neutrophil count [ANC], ferritin [adjusted for iron stat

66 her with laboratory tests (white cell count, neutrophil count and C-reactive protein), and the timing

67 The neutrophil count and leukotriene B4 concentration in bro

68 The association between neutrophil count and microvascular obstruction is abolis

69 The increase in neutrophil count and their priming is mediated by granul

70 ized by a small increase of lymphocyte B and neutrophil counts and a transient drop of total lymphocy

71 of anakinra compared with placebo on airway neutrophil counts and airway proinflammatory cytokine le

72 Profound reductions in neutrophil counts and chemotaxis as well as a diminished

73 ree barrier conditions have high circulating neutrophil counts and develop hypercellular cervical lym

74 y response in the lung as shown by increased neutrophil counts and elevated cytokine and chemokine co

75 an cluster T1, with no differences in sputum neutrophil counts and exhaled nitric oxide and serum IgE

76 , exogenous MCP-1 dose dependently increased neutrophil counts and G-CSF concentrations in the blood.

77 iglyceride, VLDL, total WBC, lymphocyte, and neutrophil counts and increase in hsCRP, total cholester

78 white blood cell, lymphocyte, monocyte, and neutrophil counts and increased adiponectin levels witho

79 Adverse events, including low neutrophil counts and increased levels of alanine aminot

80 ealed significant relationships between BALF neutrophil counts and indices of alveolar-capillary memb

81 sociated with reduced bronchoalveolar lavage neutrophil counts and interleukin-6 and macrophage infla

82 Black African participants had lower neutrophil counts and lower circulating concentrations o

83 ociated TBM and is characterized by high CSF neutrophil counts and Mycobacterium tuberculosis culture

84 clude that efforts should focus on improving neutrophil counts and on treating the frequent and serio

85 E(-/-)P(-/-)Rag-1(-/-) mice had circulating neutrophil counts and plasma G-CSF levels similar to E(-

86 in alveolar air spaces, despite normal blood neutrophil counts and survival of emigrated neutrophils,

87 Blood glucose level, total leukocyte count, neutrophil count, and leukocyte labeling efficiency vari

88 racy of the white blood cell count, absolute neutrophil count, and platelet count at commonly used th

89 PET/CT correlated with lung function, sputum neutrophil counts, and CF-CT scores.

90 y increased proinflammatory IL-1beta levels, neutrophil counts, and IL-17-shifted immunity.

91 therapy of hepatitis C causes a decrease in neutrophil counts, and neutropenia is a common reason fo

92 We also measured interleukin-17A, neutrophil counts, and total protein in bronchoalveolar

93 CXCL10, and interleukin 10 levels; increased neutrophil counts; and decreased T-helper cell type 1 re

94 Neutrophil counts are a ubiquitous measure of inflammati

95 Blood neutrophil counts are determined by the differentiation

96 In the United States, neutrophil counts are lower in black persons than in whi

97 For instance, both eosinophil and neutrophil counts are often increased in the airways of

98 Circulating neutrophil counts are positively regulated by CXCR2 sign

99 Neutrophil counts are slightly higher in Mexican-America

100 gen receptor for chemokines null variant for neutrophil count) are generalizable to WBC traits in His

101 d sham groups in the mean increment in blood neutrophil count at 8 hours (6.16 x 10(9)/L and 6.15 x 1

102 this was not the case for sex, indications, neutrophil count at initiation, and concomitant drug tre

103 n even longer ligand half-life and increased neutrophil counts at a lower dose than either wild-type

104 solation of the ST1 severe strain and higher neutrophil counts at diagnosis in two unrelated large mu

105 Recovery occurred even though blood neutrophil counts began to rise 48 hours after the last

106 d 20% each cycle to achieve a nadir absolute neutrophil count below 0.5 x 10(9)/L.

107 est that 76,000 blacks with hepatitis C have neutrophil counts below 1,500 cells/microL and might be

108 d be considered for persons with unexplained neutrophil counts below 1.0 x 10(9)/L or platelet counts

109 as observed in more than 20% of persons with neutrophil counts below 1.0 x 10(9)/L or platelet counts

110 Furthermore, comparison of neutrophil counts between the experimental and control p

111 OPD), with sputum and bronchoalveolar lavage neutrophil counts broadly correlating with disease sever

112 ing was associated with higher leukocyte and neutrophil counts but had a smaller effect among black a

113 We conclude that IL-17A regulates blood neutrophil counts by inducing G-CSF production mainly in

114 nt inhibition or depletion, depletion of BAL neutrophil counts by more than 90% with the monoclonal a

115 Peripheral neutrophil count, C-reactive protein, and proinflammator

116 openia, lung infection with grade 4 absolute neutrophil count, colon infection with grade 4 absolute

117 vement in lung function and a fall in sputum neutrophil count compared with subjects who continued to

118 8) congenics had significantly lower exudate neutrophil counts compared with DA.

119 atients had higher cerebrospinal fluid (CSF) neutrophil counts compared with non-TBM-IRIS patients (m

120 venous-arterial difference in F-actin-rimmed neutrophil counts completely accounted for sequestration

121 standard white blood cell count or absolute neutrophil count, continue to be investigated, but these

122 Although neutrophil counts continued to cycle, the range at nadir

123 Likewise, age, asthma duration, and blood neutrophil counts correctly predicted 64% of sputum neut

124 Neutrophil count correlated with the molecular degree of

125 Median absolute neutrophil count decrease was 26%, and platelet decrease

126 nts vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and

127 - 2.3 log10 cfu/ml (p<0.0001), respectively; neutrophil count decreased by 0.4 +/- 0.6 log10 cells/ml

128 Neutrophil counts decreased by 0.31 x 10(9)/L (0.09-0.54

129 During treatment, neutrophil counts decreased by an average of 34%.

130 Neutrophil counts decreased, hemoglobin and low- and hig

131 in decreased abscess size, lower circulating neutrophil counts, decreased anemia, and improved surviv

132 ude mice are neutropenic or have near-normal neutrophil counts, depending on the prevailing intestina

133 nomegaly, there was little or no decrease in neutrophil counts (despite typical decreases in platelet

134 Total WBC and neutrophil counts did not change.

135 and body temperature, and systemic absolute neutrophil counts did not differ between groups.

136 If the absolute neutrophil count dropped below 1000, the dose was reduce

137 of 3040 +/- 2540 cells/microL(P <.0001) and neutrophil counts during G-CSF administration of 10 290

138 PA syndrome revealed significantly increased neutrophil counts, erythrocyte sedimentation rates, and

139 Reduced and elevated neutrophil counts, even within the normal range, are ass

140 eno levels, IgE levels, blood eosinophil and neutrophil counts, FEV1 percent predicted, and age are p

141 neutropenia-related infections had a normal neutrophil count following treatment.

142 Total white blood cell and neutrophil counts following CLP were both significantly

143 ustained leukocytosis, due to an increase in neutrophils counts, follows.

144 nic neutropenia is defined as a low absolute neutrophil count for >6 months.

145 y predictive of time to recovery of absolute neutrophil count for both the fourth and fifth courses (

146 lood samples were drawn for determination of neutrophil counts for up to 28 d after injection.

147 Unlike the reduced neutrophil counts found in IL-17RA-deficient mice, neutr

148 ficant increase (two-fold, P < 0.05) in oral neutrophil counts found in patients with periodontitis c

149 electrocardiogram QT (five [2%]), decreased neutrophil count (four [2%]), anaemia, dyspnoea, hyponat

150 y outcomes included interleukin-8 levels and neutrophil counts from nasal wash, assessed at intake an

151 count, colon infection with grade 4 absolute neutrophil count, grade 4 changed mental status, and one

152 ndependence from transfusion and an absolute neutrophil count greater than 0.5 x 10(9) cells/L withou

153 The median times to reach an absolute neutrophil count greater than 500/microL and platelet co

154 14 days, respectively, provided an absolute neutrophil count greater than 750x10(6)/L and a platelet

155 The median time to engraftment (absolute neutrophil count > 500/mm(3) and platelets 50 000/muL) w

156 uate hepatic and renal function, an absolute neutrophil count > or = 500/microL and a platelet count

157 f all cell lineages: median time to absolute neutrophil count > or = 500/microL, 10 days versus 13 da

158 0/microL, 27% (95% CI, 18% to 36%); absolute neutrophil count >/=10000/microL, 18% (95% CI, 10% to 25

159 lower after CPX-351 (median days to absolute neutrophil count >/=1000: 36 vs 32; platelets >100 000:

160 as defined by neutrocytic ascites (absolute neutrophil count >or=250 cells/mm(3)) was 3.5%.

161 ts, mortality was associated with higher CSF neutrophil counts (hazard ratio [HR], 1.10 per 10% incre

162 ividuals were 3-fold more likely to have low neutrophil counts (HCV positive, 9% vs. HCV negative, 3%

163 GSTM1) and the use of statins, obesity, high neutrophil counts, higher blood pressure, and older age.

164 A [SAA], vascular endothelial growth factor, neutrophil count, IL-1alpha, E-selectin, intercellular a

165 otein, ceruloplasmin, and transferrin, total neutrophil count, IL-8, IL-6, tumor necrosis factor-alph

166 n drug-related adverse event was decrease in neutrophil count in 33% and 70% of the ALCL165 and ALCL2

167 dependently associated with peripheral blood neutrophil count in contacts of patients diagnosed with

168 The normal neutrophil count in the father suggests that the mutant

169 Decreased neutrophil counts in alveolar air spaces, despite normal

170 decrease in total protein concentration and neutrophil counts in alveolar fluid through bronchoalveo

171 increased absolute lymphocyte, monocyte, and neutrophil counts in blood to normal without significant

172 hibition of BAL fluid total, eosinophil, and neutrophil counts in HDM mouse asthma in vivo, as compar

173 he primary endpoint was percentage change in neutrophil counts in induced sputum 6 h after lipopolysa

174 -17RA) are all required to maintain baseline neutrophil counts in mice.

175 ansferred Rag1(-/-) or WT thymocytes correct neutrophil counts in neutropenic nude mice.

176 straints by tracking the dynamics of patient neutrophil counts in response to therapy.

177 G-CSF function in vivo significantly reduced neutrophil counts in severely neutrophilic mice by appro

178 L-17F could compensate and maintain baseline neutrophil counts in the absence of IL-17A.

179 acterial counts in the lungs, with decreased neutrophil counts in the bronchoalveolar lavage fluid as

180 Bacterial and neutrophil counts in the lung were similar in control an

181 nt to maintain the normal set point of blood neutrophil counts in vivo.

182 Total wbc and neutrophil counts increased during the experimental phas

183 cates that several BAL parameters, including neutrophil count, interleukin-8, alpha defensins and MMP

184 (4)/ml vs. 3.04 [2.82] x 10(4)/ml, p = 0.02) neutrophil counts, interleukin 8 (33.8 [189.8] vs. 16.9

185 Neutrophil counts less than 1.0 x 10(9) cells/L were obs

186 d as body temperature >/= 38.2 degrees C and neutrophil count < 0.5 x 10(9)/L on the same day of the

187 assess the duration of grade 4 neutropenia (neutrophil count < 0.5 x 10(9)/L) after one cycle of che

188 de pointes and severe neutropenia (absolute neutrophil count < or =500 cells/microL) were slightly h

189 erapy drug-induced agranulocytosis (absolute neutrophil count </=0.5 x 10(9)/L [</=500/muL]) and 5170

190 treatment discontinuation was required for a neutrophil count <0.5 x 10(9) cells/L.

191 ly 242 (8%) sustained an infection and had a neutrophil count <0.75 x 10(9) cells/L at any time while

192 Dose reduction was required for a neutrophil count <0.75 x 10(9) cells/L, and treatment di

193 estigator; 648 (21%) patients had at least 1 neutrophil count <0.75 x 10(9) cells/L, but only 242 (8%

194 The prevalence of neutropenia (neutrophil count <1.5 x 10(9) cells/L) was 4.5% among bl

195 ients with concomitant neutropenia (absolute neutrophil count <1000 cells/microL) and abdominal pain

196 A reduction in ascitic fluid neutrophil count <25% of pretreatment value was consider

197 bjects were those with neutropenia (absolute neutrophil count <500/muL) and proven/probable/presumed

198 sfusion of RBCs stored for 10 days increased neutrophil counts, macrophage inflammatory protein-2 (MI

199 Benign reductions in neutrophil counts may be more common at certain ages and

200 osinophil and tended to have a raised sputum neutrophil count (mean, 70.1%; normal, less than 65%).

201 Nine patients had increased neutrophil counts (median increase, 1350 per cubic milli

202 hereas age, FEV1 percent predicted, or blood neutrophil counts might predict sputum neutrophil percen

203 platelet count more than 75,000 x 10(6)/L, a neutrophil count more than 1,000 x 10(6)/L, and a creati

204 7 days from prior corticosteroids; absolute neutrophil count more than 1,500/microL (500/microL if d

205 The median time to absolute neutrophil count more than 500/microL after ASCR was 13

206 -) mice, resulting in very high platelet and neutrophil counts, more advanced myelofibrosis, and redu

207 Absolute neutrophil counts, motor function, Morris water maze per

208 ere decreased lymphocyte (n=3) and decreased neutrophil count (n=2); and grade 4 anaemia was reported

209 However, neither neutrophil count, Na(+) concentration, nor Na(+) : K(+)

210 s significantly associated with the absolute neutrophil count nadir (7/7 < 6/7 < 6/6, P =.02).

211 n elevated HbF without neutropenia (absolute neutrophil count nadir greater than 1500) or evidence of

212 The time to the absolute neutrophil count nadir was shorter for the (90)Y-ibritum

213 gic toxicity (assessed by blood platelet and neutrophil count nadir) (P < 0.05).

214 e were significant predictors of ln(absolute neutrophil count nadir; r(2) = 0.51).

215 t 3 experienced significantly lower absolute neutrophil count nadirs than did younger groups (P = .02

216 BAL fluid neutrophil counts negatively and positively correlated w

217 ion decline was associated with increases in neutrophil counts, neutrophil elastase, and IL-1beta and

218 xpression in mixed chimeric mice depended on neutrophil count, not iNKT cell genotype.

219 The median time to an absolute neutrophil count of 0.5 x 10(9) cells/L was 49 days.

220 The median time to achieve a neutrophil count of 0.5 x 10(9)/liter was 14 days (range

221 The median time to reach an absolute neutrophil count of 500/microL or greater was 16 days (r

222 An absolute neutrophil count of 500/microL was achieved on day +18 (

223 .22; 95% CI, 0.17-0.30), as does an absolute neutrophil count of 6750/microL or lower (LR, 0.06; 95%

224 not significantly different at the absolute neutrophil count of less than 0.5 x 109 cells/L (P = 0.5

225 nts treated with tofacitinib had an absolute neutrophil count of less than 1500.

226 ith greater risk even among individuals with neutrophil counts of 3 to 4 versus 2 to 3 x 10(9)/l.

227 (55%) with severe neutropenia had sustained neutrophil counts of greater than 1 x 10(9) cells/L.

228 ence of enzyme replacement therapy, absolute neutrophil counts of patients with ADA deficiency vary i

229 itive patients in the Oxford hospitals, mean neutrophil counts on diagnosis increased from 2003, peak

230 ts usually have minimal further decreases in neutrophil counts on therapy and are not excessively pro

231 In cyclic hematopoiesis, neutrophil counts oscillate opposite monocytes in a 3-we

232 neutropenia are cyclic neutropenia, in which neutrophil counts oscillate with a 21-day frequency, and

233 In the immediate-initiation group, average neutrophil count over follow-up was 321 cells per muL hi

234 eroxia did not further increase chemokine or neutrophil counts over normoxia.

235 ite cell count was associated with increased neutrophil count (P < 0.001) and low-grade peritumoral i

236 s A and B), age (P < 0.01), mGPS (P < 0.01), neutrophil count (P < 0.05), and Klintrup criteria (P <

237 1), temperature (P<.05), pulse rate (P<.05), neutrophil count (P<.05), tumor necrosis factor- alpha l

238 an 84% decrease in the circulating absolute neutrophil count (P<0.001) before elastase perfusion.

239 ein concentration (p=0.0003) and in absolute neutrophil count (p=0.024) at 24 h after treatment than

240 elated inversely with leukocyte and absolute neutrophil counts (P <.01) and correlated directly with

241 F showed a significant trend toward elevated neutrophil counts (P = 0.002) in BALF and increased mort

242 adjusted homocysteine levels (P<0.0001) and neutrophil counts (P<0.0001) than the no-progression gro

243 ere anaemia (nine [15%] of 62) and decreased neutrophil count, pancytopenia, and thrombocytopenia (tw

244 decreases from baseline in hemoglobin level, neutrophil count, platelet count, and weight compared wi

245 Maximum decreases in hemoglobin level, neutrophil count, platelet count, and weight during ther

246 lar lavage IL-8 (R(2) = 0.20, P = 0.004) and neutrophil count (R(2) = 0.21, P = 0.001).

247 ses intravenous immunoglobulins allowed full neutrophil count recovery.

248 (18)F-FLT changes preceded neutrophil count reductions.

249 re and treatment duration, only decreases in neutrophil count remained associated with virologic resp

250 Neutrophil counts remained unchanged.

251 so showed decreased lymphocyte and increased neutrophil counts, respectively.

252 Even after neutrophil counts return to near normal levels, patients

253 Neutrophil counts returned to normal after cessation of

254 as the 7-day period centered on the day the neutrophil count rose above 1000/mm3 [day 0]) and to com

255 After the injection of lentivirus, mean neutrophil counts +/- SD were 12 460 +/- 4240 cells/micr

256 White blood cell and neutrophil counts, serum or plasma levels of fibrinogen,

257 Neutrophil counts should be carefully evaluated in prema

258 during the first 11 days (difference between neutrophil count slopes 0.34 x 10(9)/L/day; 95% CI 0.12-

259 risk factors and acute conditions affecting neutrophil counts (such as infections and cancer).

260 ent, group A had higher median leukocyte and neutrophil counts than group B (P < .001).

261 re anaemia (seven [12%] of 59) and decreased neutrophil count (three [5%]); an additional six events

262 The median time to recovery of absolute neutrophil count to >/= 500 cells/microL was 11 days (ra

263 ic patients as 100% increase in the absolute neutrophil count to more than 5 x 10(8) cells per L, and

264 a, decreased lymphocyte count, and decreased neutrophil count (two [3%] each).

265 nt, AIDS, antiretroviral therapy, cirrhosis, neutrophil count, type of peg-IFN, and granulocyte colon

266 tality and biomarkers of inflammation (blood neutrophil count, urea, and creatinine concentrations) c

267 Androgen supplement can restore neutrophil counts via stabilizing AR in castrated mice,

268 nulocyte colony-stimulating factor until the neutrophil count was 1 x 10(9)/liter for 2 consecutive d

269 The median presenting absolute neutrophil count was 100/muL.

270 A significant increase in neutrophil count was also demonstrated starting on the t

271 arrow was enhanced, and the peripheral blood neutrophil count was also substantially elevated in thes

272 Lymphopenia was universal, but the neutrophil count was generally not affected.

273 receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 x 10(9)/L (or for

274 Compared with control, systemic absolute neutrophil count was increased more than ten-fold in gra

275 timulating factor was used when the absolute neutrophil count was less than 1,000/microL.

276 one from infection (although their absolute neutrophil count was normal), which was definitely relat

277 Time-updated neutrophil count was not associated with severe bacteria

278 Reduced sputum neutrophil count was observed among the 122 patients exa

279 The total white blood cell and neutrophil count was reduced from 7610 to 6980 cells/mic

280 Nadir lymphocyte count, not nadir neutrophil count, was independently associated with mode

281 This activation, like the drop in neutrophil count, was transient.

282 ctin, TNFalpha, and MPO and peripheral blood neutrophil count were higher in patients with RA than co

283 Median change in interleukin-8 levels and neutrophil counts were also not statistically significan

284 Blood neutrophil counts were elevated (4.8x), whereas lymphocy

285 ients of WT stem cells; however, circulating neutrophil counts were higher only in Rac2(-/-) recipien

286 s with the strongest relationships to sputum neutrophil counts were IL1R1 (standardized regression co

287 that 24 hours after infection macrophage and neutrophil counts were lower in the cornea of Lum(-/-) m

288 phil counts found in IL-17RA-deficient mice, neutrophil counts were mildly increased in IL-17A-defici

289 differences in hemoglobin concentrations and neutrophil counts were no longer significant, whereas di

290 Lung edema, cytokines, and neutrophil counts were reduced after EVLP and further, s

291 re normal, in both fetus and newborn animals neutrophil counts were significantly depressed relative

292 Bacterial counts and neutrophil counts were significantly higher in the circu

293 As reported in the literature, sputum neutrophil counts were significantly increased in subjec

294 tney U test; P = .012) and day-14 (P = .025) neutrophil counts were significantly lower in patients r

295 Age, FEV1 percent predicted, and blood neutrophil counts were similarly unsatisfactory for the

296 Neutrophil counts were strongly associated with the inci

297 of depression, and female sex, but not nadir neutrophil count, were associated with moderate, severe,

298 ef review summarizes the regulation of blood neutrophil counts, which is in part controlled by G-CSF,

299 stigated associations of clinically recorded neutrophil counts with initial presentation for a range

300 to dosage-related decreases in the absolute neutrophil count, with a median decrease of 38% in the 4